Infectious Disease, Respirology

RSV Prevention for All Infants: From NACI Guidelines to Clinical Application

This is a 15-minute expert brief for Canadian primary care providers and other healthcare professionals. Due to the limited therapeutic options available to manage RSV disease, the goal is to provide education on disease prevention. This expert brief is designed to provide practical information on passive immunization options available for infants in Canada, with a focus on NACI’s recommendations for the use of nirsevimab, the recently authorized long-acting monoclonal antibody. The expert brief video will feature a conversation between a Pediatric Infectious Disease Specialist and a Family Physician.

DURATION

15 min

PROFESSION

Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist

# OF CREDITS

0

ACCREDITATION

Unaccredited

EXPIRY DATE

2025-05-09

Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. RSV is also the leading cause of infant hospitalizations in Canada, resulting in significant disease burden and impacts on the Canadian health system. Considering the substantial burden of disease on all infants, NACI has recently issued new recommendations towards a universal RSV immunization program, with the use of nirsevimab to prevent severe RSV disease. In 2023, two new products were authorized by Health Canada for use in RSV immunization programs: nirsevimab, a long-acting monoclonal antibody, and RSVpreF, a maternal vaccine. The available efficacy (including duration of protection) and safety data for RSVpreF and nirsevimab underpin NACI’s preferential recommendation for nirsevimab.


This program has received an unrestricted educational grant or in-kind support from Sanofi.

Faculty

Christine Palmay, MD, CCFP, FCFP

Wendy Vaudry, MD, CM, FRCPC

Learning objectives

After viewing this expert brief, participants will be better able to:

  • Recognize the burden of RSV disease in all infants
  • Summarize NACI guidance for a universal RSV immunization program
  • Implement RSV immunoprophylaxis in clinical practice
Cost of course:  
Free
# of credits: 0
Duration: 15 min

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

RSV Prevention for All Infants: From NACI Guidelines to Clinical Application

15 min

Duration

Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist

Profession

0

# of credits

Learning Objectives

After viewing this expert brief, participants will be better able to:

  • Recognize the burden of RSV disease in all infants
  • Summarize NACI guidance for a universal RSV immunization program
  • Implement RSV immunoprophylaxis in clinical practice

Unaccredited

ACCREDITATION

Infectious Disease, Respirology

Learning Category

Respiratory, Infectious Disease

Topic

0

Price

2025-05-09

Expiry Date

CAN-eng

Region/Language

Course Description

Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. RSV is also the leading cause of infant hospitalizations in Canada, resulting in significant disease burden and impacts on the Canadian health system. Considering the substantial burden of disease on all infants, NACI has recently issued new recommendations towards a universal RSV immunization program, with the use of nirsevimab to prevent severe RSV disease. In 2023, two new products were authorized by Health Canada for use in RSV immunization programs: nirsevimab, a long-acting monoclonal antibody, and RSVpreF, a maternal vaccine. The available efficacy (including duration of protection) and safety data for RSVpreF and nirsevimab underpin NACI’s preferential recommendation for nirsevimab.


This program has received an unrestricted educational grant or in-kind support from Sanofi.

Faculty

Christine Palmay, MD, CCFP, FCFP

Wendy Vaudry, MD, CM, FRCPC

Accreditation

Unaccredited